LAMEA myocardial infarction market is estimated to grow at the fastest CAGR of around 5.2% during the forecast period. The market is growing considerably owing to the increasing prevalence of hypertension and CVD. As per the study conducted by the Wits University scientists, South Africa has the largest prevalence of hypertension in the southern African region. The increasing prevalence of hypertension raises the possibility of a heart attack in the region.

Request a Free Sample of our Report on LAMEA Myocardial Infarction Market: https://www.omrglobal.com/request-sample/lamea-myocardial-infarction-market

As per the data published by the Ministry of Health and Prevention (MOHAP), UAE, in September 2019, the prevalence of hypertension in the country has recorded 28.8%. This represents a significant number of hypertensive patients in the country. This rising hypertension among patients in South Africa and UAE is expected to boost the adoption of diagnosis and treatment procedures for myocardial infarction, to reduce the possibility of occurrence of severe conditions, including heart attack.

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

A Full Report of LAMEA Myocardial Infarction Market is Available at
https://www.omrglobal.com/industry-reports/lamea-myocardial-infarction-market

Myocardial Infarction Market

By Type
• Non-ST-elevation myocardial infarction (NSTEMI)
• ST-elevation myocardial infarction (STEMI)
• Silent Heart Attacks

By Device
• Left Ventricular Assist Device (LVAD)
• Pacemaker
• Catheters
• Implantable Cardioverter-Defibrillator (ICD)
• Others (Stent Graft)

By Diagnosis
• Electrocardiography (ECG)
• Chest X-Ray
• Computed Tomography (CT Scan)
• Echocardiography
• Others (Blood Test)

By Treatment
• Medication
o Analgesics
o Thrombolytic
o Antiplatelet Agents
o Glycoprotein IIb/IIIa Inhibitors
o Others (Beta-Adrenergic Blockers)
• Surgery
o Angioplasty
o Bypass Surgery
o Heart Transplant

By End-User
• Hospital & Clinics
• Ambulatory Surgical Centers
• Research Institutes

Regional Analysis
• Brazil
• Argentina
• UAE
• Kenya
• South Africa
• Nigeria
• Rest of LAMEA

Company Profiles
• Abbott Laboratories Inc.
• AstraZeneca PLC
• Bayer AG
• Boston Scientific Corp.
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Merck KGaA
• Mylan N.V.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/lamea-myocardial-infarction-market

About us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404